Scientific Opportunities with an X-ray Free-Electron Laser Oscillator

An X-ray free-electron laser oscillator (XFELO) is a new type of hard X-ray source that would produce fully coherent pulses with meV bandwidth and stable intensity. The XFELO complements existing sources based on self-amplified spontaneous emission (SASE) from high-gain X-ray free-electron lasers (XFEL) that produce ultra-short pulses with broad-band chaotic spectra. This report is based on discussions of scientific opportunities enabled by an XFELO during a workshop held at SLAC on June 29 - July 1, 2016Comment: 21 pages, 12 figure

Populating a cluster of galaxies - I. Results at z=0

We simulate the assembly of a massive rich cluster and the formation of its constituent galaxies in a flat, low-density universe. Our most accurate model follows the collapse, the star-formation history and the orbital motion of all galaxies more luminous than the Fornax dwarf spheroidal, while dark halo structure is tracked consistently throughout the cluster for all galaxies more luminous than the SMC. Within its virial radius this model contains about 2.0e7 dark matter particles and almost 5000 distinct dynamically resolved galaxies. Simulations of this same cluster at a variety of resolutions allow us to check explicitly for numerical convergence both of the dark matter structures produced by our new parallel N-body and substructure identification codes, and of the galaxy populations produced by the phenomenological models we use to follow cooling, star formation, feedback and stellar aging. This baryonic modelling is tuned so that our simulations reproduce the observed properties of isolated spirals outside clusters. Without further parameter adjustment our simulations then produce a luminosity function, a mass-to-light ratio, luminosity, number and velocity dispersion profiles, and a morphology-radius relation which are similar to those observed in real clusters. In particular, since our simulations follow galaxy merging explicitly, we can demonstrate that it accounts quantitatively for the observed cluster population of bulges and elliptical galaxies.Comment: 28 pages, submitted to MNRA

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study

Background: Decision-making for or against neoadjuvant or adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer does not follow any clear guidelines, and some patients may unnecessarily undergo chemotherapy and be exposed to the associated toxicity. The aim of this study was to identify the patient population for whom this issue may bear relevance. Methods: Patients being treated with letrozole in the prospective multicenter noninterventional EvAluate-TM study were recruited. The percentage of patients receiving chemotherapy and factors associated with chemotherapy administration were identified. Results: In all, 3,924 (37.4%) patients received chemotherapy before treatment with letrozole. Of these, 293 (20%) underwent neoadjuvant therapy. Younger age was predictive for both adjuvant and neoadjuvant therapy. Overall, decisions in favor of administering chemotherapy are more likely to be made in patients with a higher body mass index (BMI), and neoadjuvant chemotherapy is administered at a higher rate in women with a lower BMI. Concomitant medication influenced the overall decision-making regarding chemotherapy, irrespective of whether it was given on a neoadjuvant or adjuvant basis. Conclusion: There is an ongoing debate as to whether all of the many patients who receive chemotherapy actually benefit from it. Neoadjuvant chemotherapy is frequently administered in this patient population, and this should encourage further research to resolve current clinical and research issues

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Background: Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients. Methods: EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor–positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT. Results: Out of 200 patients, 66 patients terminated treatment prematurely, 26 (13%) of them due to causes other than disease progression. Persistence rate for reasons other than progression at 12 months was 77.7%. Persistence was lower in patients who reported any adverse event (AE) in the first 30 days of ET (89.5% with no AE and 56% with AE). Furthermore, patients had a lower persistence if they reported compliance problems in the past before letrozole treatment. Conclusions: Despite suffering from a life-threatening disease, AEs of an AI will result in a relevant number of treatment terminations that are not related to progression. Some subgroups of patients have very low persistence rates. Especially with regard to novel endocrine combination therapies, these data imply that some groups of patients will need special attention to guide them through the therapy process. Trial registration Clinical Trials Number: CFEM345DDE1

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Purpose The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only a few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define a subset of patients who received only endocrine therapy. We present 3-year outcome data and concordance analysis (among biomarkers/RS). Patients and Methods Central tumor bank was established prospectively from PlanB (intermediate and high-risk, locally human epidermal growth factor receptor 2-negative BC). After an early amendment, HR-positive, pN0-1 patients with RS <= 11 were recommended to omit chemotherapy. Results From 2009 to 2011, PlanB enrolled 3,198 patients with a median age of 56 years; 41.1% had node-positive and 32.5% grade 3 disease. In 348 patients (15.3%), chemotherapy was omitted based on RS <= 11. After 35 months median follow-up, 3-year disease-free survival in patients with RS <= 11 and endocrine therapy alone was 98% versus 92% and 98% in RS. 25 and RS 12 to 25 in chemotherapy-treated patients, respectively. Nodal status, central and local grade, the Ki-67 protein encoded by the MKI67 gene, estrogen receptor, progesterone receptor, tumor size, and RS were univariate prognostic factors for disease-free survival; only nodal status, both central and local grade, and RS were independent multivariate factors. Histologic grade was discordant between central and local laboratories in 44%. RS was positively but moderately correlated with the Ki-67 protein encoded by the MKI67 gene and grade and negatively correlated with progesterone receptor and estrogen receptor. Conclusion In this prospective trial, patients with enhanced clinical risk and omitted chemotherapy on the basis of RS <= 11 had excellent 3-year survival. The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor-positive BC. (C) 2016 by American Society of Clinical Oncolog

ZMI - Newsletter 3/2003

"Grenzen der Interaktivität" Konferenz am ZMI am 13./14./15. November 2003 - DFG bewilligt ZMI-Projekt "Web-Unsability" - 70.000 € vom JLU-Förderfonds für das ZMI-Projekt "eLearning-Plattform" - ZMI-Zielvereinbarungen unterschriftsreif - Azubi im ZMI - Ute Zimmermann schreibt für die FAZ - Carolin Fuchs Stipendiatin der Hans Böckler Stiftung - "Markt, Politik, Identität - Ursachen und Folgen sozialer Beschleunigung" - Prof. Groß über "Informatisierung der Verwaltung" - Neuer Master-Studiengang "Sprachtechnologie und Fremdsprachendidaktik" - Projekt "Didaktik des frühen Fremdsprachenlernens" - Prof. Rösler in Korea - Prof. Legutke in Birmingham - Communicator-Preis für Wolf Singer - Der ZMI-Fernseh-Tipp: "Games-Odyssey"